SRPT - Sarepta TherapeuticsAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $69.99 | Open | $70.47 |
| Volume | 394.3K | Market Cap | 5.51B |
| Yield | Last Dividend |
| RBC Capital Stick to Their Buy Rating fo... | 04/11/21 |
| RBC Capital Stick to Their Buy Rating for Sarepta Therapeutics | |
| Needham Stick to Their Buy Rating for Sa... | 03/19/21 |
| Needham Stick to Their Buy Rating for Sarepta Therapeutics | |
| The Daily Biotech Pulse: Sarepta Gene Th... | 03/19/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 18) An... | |
| Mizuho Securities Stick to Their Buy Rat... | 03/19/21 |
| Mizuho Securities Stick to Their Buy Rating for Sarepta Therapeutics | |
| Orsini Specialty Pharmacy Selected By Sa... | 03/04/21 |
| ELK GROVE VILLAGE, Ill. , March 4, 2021 /PRNewswire/ -- Orsini Specialty Pharmacy, the leading independent specialty pharmacy focused on rare diseases... | |
| Robert W. Baird Stick to Their Buy Ratin... | 03/02/21 |
| Robert W. Baird Stick to Their Buy Rating for Sarepta Therapeutics | |
| Sarepta Therapeutics (NASDAQ:SRPT) Relea... | 03/01/21 |
| Sarepta Therapeutics (NASDAQ:SRPT) released its quarterly earnings data on Monday. The biotechnology company reported ($1.84) earnings per share (EPS)... | |
| Recap: Sarepta Therapeutics Q4 Earnings | 03/01/21 |
| Shares of Sarepta Therapeutics (NASDAQ:SRPT) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per s... | |
| Sarepta Therapeutics Wall street estimat... | 03/01/21 |
| Sarepta Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? | |
| Attention Biotech Investors: Mark Your C... | 02/28/21 |
| Most Food and Drug Administration decisions scheduled for February were positive, and more importantly five new molecular entities passed FDA muster. ... | |
| Earnings Preview: Sarepta Therapeutics | 02/26/21 |
| Sarepta Therapeutics (NASDAQ:SRPT) announces its next round of earnings this Monday, March 01. Here is Benzinga's everything-that-matters guide for th... | |
| Gene therapy leaders may need M&A to sol... | 02/24/21 |
| Summary List Placement Reports of patients deaths, cancer cases, and other potential safety issues in the gene therapy field have made some investors ... | |
| The Daily Biotech Pulse: Bausch Calls Tr... | 02/24/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 23) Axo... | |
| The Week Ahead In Biotech: J&J Vaccine A... | 02/20/21 |
| Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pa... | |
| This Is What Hedge Funds Bought And Sold... | 02/16/21 |
| This Is What Hedge Funds Bought And Sold In Q4: Complete 13F Summary In the aftermath of late January's massive short squeeze fireworks, 13F reporting... | |
| ONGOING INVESTIGATION ALERT: The Schall ... | 02/01/21 |
| LOS ANGELES, Feb. 1, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claim... | |
| Finalise policy on rare diseases by Mar:... | 01/28/21 |
| New Delhi: The Delhi High Court on Thursday directed the Centre to finalise by March 31 its new National Health Policy for Rare Diseases of 2020 and m... | |
| Finalise policy on rare diseases by Marc... | 01/28/21 |
| New Delhi, January 28 The Delhi High Court on Thursday directed the Centre to finalise by March 31 its new National Health Policy for Rare Diseases of... | |
| FXNEWS24 |After A 50% Fall Sarepta Thera... | 01/25/21 |
| After A 50% Fall Sarepta Therapeutics Stock Now Looks Attractive | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News | |
| Duchenne Muscular Dystrophy (DMD) Treatm... | 01/14/21 |
| The Duchenne Muscular Dystrophy (DMD) Treatment Market is expected to have a highly positive outlook over the forecast period 2020-2027 according to a... | |
| Sarepta (SRPT) Looks Good: Stock Adds 9.... | 01/12/21 |
| Sarepta (SRPT) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes. | |
| SRPT EQUITY ALERT: ROSEN, GLOBAL INVESTO... | 01/09/21 |
| NEW YORK, Jan. 9, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on... | |
| Merrill Lynch Stick to Their Buy Rating ... | 01/09/21 |
| Merrill Lynch Stick to Their Buy Rating for Sarepta Therapeutics | |
| SRPT INVESTIGATION ALERT: Bernstein Lieb... | 01/08/21 |
| NEW YORK, Jan. 8, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities frau... | |
| INVESTIGATION ALERT: The Schall Law Firm... | 01/08/21 |
| LOS ANGELES--(BUSINESS WIRE)---- $SRPT #SRPT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeuti... | |
| SRPT EQUITY ALERT: Rosen Law Firm Announ... | 01/08/21 |
| NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of s... | |
| Tesla, Micron Technology, Sarepta Therap... | 01/08/21 |
| Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalitie... | |
| Sarepta Falls 50% To 10-Month Low After ... | 01/08/21 |
| Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT ), which had a lot riding on its gene therapy candidate for treating Duchenne muscular dystrophy in t... | |
| Stocks making the biggest moves in the p... | 01/08/21 |
| The stocks making the biggest moves in premarket trading include Tesla, Micron Technology, Sarepta Therapeutics & more. | |
| Needham Stick to Their Buy Rating for Sa... | 01/08/21 |
| Needham Stick to Their Buy Rating for Sarepta Therapeutics | |
| Strong Buy rating | 03/02/21 |
| SVB Leerink maintains Outperform rating and raises Price Target from $125.00 to $126.00 | |
| Buy rating | 02/26/21 |
| Mizuho maintains Buy rating and raises Price Target from $158.00 to $160.00 | |
| Date | 2021-03-01 (AMC) | Est. (EPS/Rev.) | ($1.77)/ 146.29M |
| Actual (EPS/Rev.) | $-1.84/ $145.14 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Tech Trades | Tech Trades | 82.00 % | Follow |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| TechEvent Trading | TechEvent Investor | 61.00 % | Subscribe |
| King of Analysts (KoA) | King of Analysts | 60.00 % | Subscribe |
| BAWSDAQ | karan1703 | 59.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
